Manufacturing and characterizing AAV-based vectors for use in clinical studies (Q37140657)

18 August 2017

1 reference

title

Manufacturing and characterizing AAV-based vectors for use in clinical studies (English)

1 reference

18 August 2017

J F Wright

1

1 reference

18 August 2017

publication date

17 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

15

1 reference

18 August 2017

issue

11

1 reference

18 August 2017

page(s)

840-848

1 reference

https://scigraph.springernature.com/pub.10.1038/gt.2008.65

18 August 2017

exact match

0 references

cites work

Adeno-associated virus vectors in clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Treatment of human disease by adeno-associated viral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Current status of gene therapy trials for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

CD8(+) T-cell responses to adeno-associated virus capsid in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Novel tools for production and purification of recombinant adenoassociated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Adeno-associated virus vectors can be efficiently produced without helper virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Cell lines for the production of recombinant adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Insect cells as a factory to produce adeno-associated virus type 2 vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Economized large-scale production of high yield of rAAV for gene therapy applications exploiting baculovirus expression system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Quantification of adeno-associated virus particles and empty capsids by optical density measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Production of clinical-grade recombinant adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Serum-free production and column purification of adeno-associated virus type 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Herpesvirus-based infectious titering of recombinant adeno-associated viral vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

7 January 2021

Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

7 January 2021

Streamlined large-scale production of recombinant adeno-associated virus (rAAV) vectors

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

7 January 2021

Factors affecting the efficiency of CD8+ T cell cross-priming with exogenous antigens

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.65

7 January 2021

Identifiers

DOI

10.1038/GT.2008.65

1 reference

18 August 2017

1 reference